Reduced Cardiovascular Capacity and Resting Metabolic Rate in Men with Prostate Cancer Undergoing Androgen Deprivation: A Comprehensive Cross-Sectional Investigation. (26th October 2015)

• Record Type: Journal Article
• Authors: Wall, Bradley A.; Galvão, Daniel A.; Fatehee, Naeem; Taaffe, Dennis R.; Spry, Nigel; Joseph, David; Newton, Robert U.
• Other Names: Chang In Ho Academic Editor.
• Is Part Of: Advances in urology. Volume 2015(2015)
• Publication Date: 2015-10-26
• Subjects: Urology -- Periodicals; 616.6005
• DOI: 10.1155/2015/976235
• Languages: English
• ISSNs: 1687-6369

Abstract

Abstract : Objectives . To investigate if androgen deprivation therapy exposure is associated with additional risk factors for cardiovascular disease and metabolic treatment-related toxicities. Methods . One hundred and seven men (42–89 years) with prostate cancer undergoing androgen deprivation therapy completed a maximal graded objective exercise test to determine maximal oxygen uptake, assessments for resting metabolic rate, body composition, blood pressure and arterial stiffness, and blood biomarker analysis. A cross-sectional analysis was undertaken to investigate the potential impact of therapy exposure with participants stratified into two groups according to duration of androgen deprivation therapy (<3 months and ≥3 months). Results . Maximal oxygen uptake (26.1 ± 6.0 mL/kg/min versus 23.2 ± 5.8 mL/kg/min, p = 0.020 ) and resting metabolic rate (1795 ± 256 kcal/d versus 1647 ± 236 kcal/d, p = 0.005 ) were significantly higher in those with shorter exposure to androgen deprivation. There were no differences between groups for peripheral and central blood pressure, arterial stiffness, or metabolic profile. Conclusion . Three months or longer exposure to androgen deprivation therapy was associated with reduced cardiorespiratory capacity and resting metabolic rate, but not in a range of blood biomarkers. These findings suggest that prolonged exposure to androgen deprivation therapy is associated with negative alterations in cardiovascular outcomes. Trial registry is:ACTRN12609000200280 .